Valuation: REGENXBIO Inc.

Market Cap 619M 531M 499M 456M 860M 59.06B 864M 5.9B 2.29B 29.79B 2.32B 2.27B 98.68B P/E 2026 *
-2.85x
P/E 2027 * -3.5x
Enterprise Value 610M 524M 492M 449M 848M 58.23B 852M 5.82B 2.26B 29.37B 2.29B 2.24B 97.29B EV / Sales 2026 *
3.64x
EV / Sales 2027 * 3.1x
Free-Float
93.73%
Yield 2026 *
-
Yield 2027 * -
1 day+5.27%
1 week-21.96%
Current month-3.20%
1 month-3.60%
3 months+48.65%
6 months+7.20%
Current year-34.86%
1 week 7.77
Extreme 7.77
11.16
1 month 7.77
Extreme 7.77
12.08
Current year 5.46
Extreme 5.455
16.19
1 year 5.46
Extreme 5.455
16.19
3 years 5.04
Extreme 5.035
28.8
5 years 5.04
Extreme 5.035
46.46
10 years 5.04
Extreme 5.035
85.1
Manager TitleAgeSince
Chief Executive Officer 64 2024-06-30
Director of Finance/CFO 45 2024-09-15
Chief Tech/Sci/R&D Officer 53 2025-02-28
Director TitleAgeSince
Chairman 78 2020-06-30
Chairman 51 2024-06-30
Director/Board Member 76 2015-10-14
Date Insider Type Main position Quantity % Market Cap.
8/1/26 Tax

Chief Technology Officer

-7,468 0.0114%
8/1/26 Tax

General Counsel

-4,699 0.0072%
7/2/26 Fiscal year

Chief Technology Officer

6,483 0.0125%
Change 5-day change 1-year change 3-year change Capi.($)
+5.27%-21.96%+2.85%-48.32% 619M
+3.31%-3.70%+61.03%+103.64% 70.42B
+2.09%+2.28%+49.95%+91.30% 65.4B
-1.31%-0.50%+7.41%-4.29% 28.28B
-1.56%+0.64%+57.30%+10.41% 26.57B
+0.40%-4.80%-5.89%+469.55% 27.16B
-1.68%+0.33%+36.86%-16.09% 20.09B
+1.02%+6.43%+269.42%+420.34% 20.61B
+1.63%-1.22%+13.62%+546.01% 15.87B
-1.09%+3.14%+46.32%+155.12% 13.9B
Average +0.76%-1.15%+53.89%+172.77% 28.89B
Weighted average by Cap. +1.02%+0.67%+56.39%+156.83%

Financials

2026 *2027 *
Net sales 168M 144M 135M 123M 233M 16B 234M 1.6B 620M 8.07B 630M 616M 26.74B 217M 186M 175M 160M 301M 20.7B 303M 2.07B 802M 10.44B 815M 797M 34.59B
Net income -176M -151M -142M -130M -244M -16.79B -246M -1.68B -650M -8.47B -661M -647M -28.06B -200M -172M -161M -147M -278M -19.1B -279M -1.91B -740M -9.63B -752M -735M -31.91B
Net Debt -8.72M -7.48M -7.02M -6.41M -12.11M -832M -12.16M -83.12M -32.21M -420M -32.74M -32.02M -1.39B 53.61M 46.02M 43.19M 39.45M 74.45M 5.11B 74.81M 511M 198M 2.58B 201M 197M 8.54B
Logo REGENXBIO Inc.
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Employees
371
Date Price Change Volume
26-08-26 US$9.380 +5.27% 1,160,019
26-08-25 US$8.910 +10.61% 1,756,781
26-08-24 US$8.055 -24.86% 5,446,547
26-08-21 US$10.72 -3.07% 1,007,024
26-08-20 US$11.06 -7.99% 947,369
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
9.380USD
Average target price
23.73USD
Spread / Average Target
+152.96%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RGNX Stock